Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Allogene Therapeutics Inc

ALLO
Current price
2.69 USD -0.2 USD (-6.92%)
Last closed 2.59 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 540 750 528 USD
Yield for 12 month -55.83 %
1Y
3Y
5Y
10Y
15Y
ALLO
21.11.2021 - 28.11.2021

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California. Address: 210 East Grand Avenue, South San Francisco, CA, United States, 94080

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

11.65 USD

P/E ratio

Dividend Yield

Current Year

+95 000 USD

Last Year

+243 000 USD

Current Quarter

+22 000 USD

Last Quarter

+21 000 USD

Current Year

-242 819 000 USD

Last Year

+243 000 USD

Current Quarter

-3 533 000 USD

Last Quarter

-54 640 000 USD

Key Figures ALLO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -270 656 992 USD
Operating Margin TTM -315927.27 %
PE Ratio
Return On Assets TTM -26.71 %
PEG Ratio
Return On Equity TTM -55.48 %
Wall Street Target Price 11.65 USD
Revenue TTM 87 000 USD
Book Value 2.71 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -26.7 %
Dividend Yield
Gross Profit TTM 243 000 USD
Earnings per share -1.78 USD
Diluted Eps TTM -1.78 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics ALLO

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ALLO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation ALLO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 3041.827
Price Sales TTM 6763.6797
Enterprise Value EBITDA -0.9623
Price Book MRQ 1.2544

Financials ALLO

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ALLO

For 52 weeks

2.23 USD 6.12 USD
50 Day MA 3.65 USD
Shares Short Prior Month 31 360 608
200 Day MA 3.55 USD
Short Ratio 18.04
Shares Short 33 867 289
Short Percent 30.74 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

425.34 USD Microsoft Corporation +5.34 (+1.27%)
Detailed analytics

ETF funds


S

SX7EEX

14.76 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) +0.11 (+0.7%)
Detailed analytics

Metals


Gold

2415.8 USD Gold +1.74 (+0.07%)
Detailed analytics